NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com),
a clinical-stage pharmaceutical company focused on the development
of oral drug delivery systems, today announced results from a
diabetes market survey conducted for Oramed by a third party
research firm. The survey included qualitative interviews with
healthcare providers as well as type 1 (T1D) and type 2 (T2D)
diabetes patients regarding Oramed's lead oral insulin product,
ORMD-0801, which is headed into a Phase III trial.
Forty-one health care providers, including 22 endocrinologists
and 19 primary care physicians, nurse practitioners, physician
assistants and certified diabetes educators were surveyed. There
was strong support among these health care providers for use of
oral insulin with T2D patients early in the treatment process
through a primary care physician before the need for injectable
insulin and before the patient is moved to an endocrinologist for
diabetes care. ORMD-0801 resonated well with health care providers
because of the potential for ORMD-0801 to not cause hypoglycemia or
weight gain, as well as the advantage of being an oral medication
that does not require needles. Overall, health care providers
stated they would "strongly recommend oral insulin" for:
- T2D patients currently on oral medication;
- T2D patients who are candidates for insulin; and
- T2D patients who are candidates for basal insulin.
Forty T1D and T2D patients were surveyed and responded with a
high degree of interest, stating oral administration of insulin is
"extremely important" or "very important."
- 91% of T1D patients surveyed stated they were "extremely
likely" or "very likely" to ask their doctors about ORMD-0801;
- 85% of T2D patients surveyed stated they were "extremely
likely" or "very likely" to ask their doctors about ORMD-0801;
and
- 80% of T2D patients surveyed stated oral administration is
"extremely important" or "very important", in particular to delay
injectable insulin.
Oramed's Chief Executive Officer, Nadav
Kidron, commented, "This latest market survey further
confirms the value of our oral insulin capsule. The very high
degree of interest from patients and the receptivity of doctors for
an oral insulin that can be prescribed early in the treatment
process combine to give us a clear picture of where ORMD-0801 fits
in the diabetes care market. Of course, patients should discuss all
medication options with their healthcare providers. As we
move into our Phase III study, we will be in active contact with
stakeholders including health care providers, payers and
patients."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in
the field of oral delivery solutions for drugs currently delivered
via injection. Established in 2006, with offices in New
York and Israel, Oramed has developed a novel Protein
Oral Delivery (POD™) technology. Oramed is seeking to revolutionize
the treatment of diabetes through its proprietary lead
candidate, ORMD-0801, which has the potential to be the first
commercial oral insulin capsule for the treatment of
diabetes. The Company has completed multiple Phase II clinical
trials under an Investigational New Drug application with
the U.S. Food and Drug Administration. In addition, Oramed is
developing an oral GLP-1 (Glucagon-like peptide-1) analog
capsule, ORMD-0901.
For more information, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss heading into a Phase III
trial, the potential benefits of ORMD-0801, the interest in and
receptivity and support for ORMD-0801 by patients and health care
providers if it is approved or revolutionizing the treatment of
diabetes with our products. In addition, historic results of
scientific research and clinical trials do not guarantee that the
conclusions of future research or trials will suggest identical or
even similar conclusions. These forward-looking statements are
based on the current expectations of the management of Oramed only,
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or
delays in obtaining regulatory approval or patent protection for
our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional
funding required to conduct our research, development and
commercialization activities. In addition, the following factors,
among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in
technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to
timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress
further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose
knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our
process; greater cost of final product than anticipated; loss of
market share and pressure on pricing resulting from competition;
laboratory results that do not translate to equally good results in
real settings; our patents may not be sufficient; and finally that
products may harm recipients, all of which could cause the actual
results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as
otherwise required by law, Oramed undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with
the Securities and Exchange Commission.
Company Contact
Estee
Yaari
+1-844-9-ORAMED
estee@oramed.com
View original
content:http://www.prnewswire.com/news-releases/orameds-diabetes-market-survey-shows-strong-support-for-ormd-0801-oral-insulin-among-physicians-and-patients-301131194.html
SOURCE Oramed Pharmaceuticals Inc.